NCT05422885CompletedPhase 1/2
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging
Source: ClinicalTrials.gov · Last updated 17 Mar 2025
Brief summary (registry, in English)
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 14 Mar 2022
- Start date
- 20 May 2022
- Primary completion date
- 24 Jan 2024
- Lead sponsor
- Lewis Lipsitz
- Diseases
- Alzheimer disease
- NCT number
- NCT05422885
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 15
- From 20 May 2022 to the primary completion date, 24 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unwilling to take study medications or follow study protocol
- Drug or alcohol abuse in the last 5 years,
Other illness
- Allergies to Dasatinib or Quercetin,
- Unstable coronary artery disease (myocardial infarction within 6 months or angina),
- Stroke or transient ischemic attack in the past 6 months,
- Chronic heart failure,
- Current or chronic history of liver disease,
- Neurodegenerative disease including Parkinson's disease,
- Chronic renal disease,
- History or current diagnosis of pulmonary hypertension,
Lab values
- QTc prolongation,
- Prolonged prothrombin time or INR,
- Chronic use of any of the following medications: anti-arrhythmic medications, antipsychotics, anxiolytics, anti-platelet or anti-coagulant medications other than aspirin, quinolone antibiotics, or drugs metabolized by the same liver enzymes as Quercetin or Dasatinib.
Other
- Telephone MoCA score \<10 points
- Inability to independently perform Katz Activities of Daily Living (ADLs),
- Hospitalization within 6 months,
- Anemia,
- Thrombocytopenia,
- Neutropenia,
- Indications of current fluid retention,
- Inability to insonate the middle cerebral artery through a temporal bone window on at least one side using transcranial Doppler ultrasound, or
Who the study is looking for
- Men and women \>/= 65 years
- Ambulatory,
- Community dwelling,
- Slow gait speed (\<1 m/second),
- Mild Cognitive Impairment (Telephone MoCA score \<21, which is indicative of cognitive impairment)
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hebrew Senior Life Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.